Phase III ADAURA: Adjuvant Osimertinib vs Placebo After Complete Resection in Patients With Stage IB-IIIA EGFR-Mutated NSCLC

May 29-31, 2020; Online at meetings.asco.org/am
Adjuvant osimertinib associated with significantly improved disease-free survival after complete resection in patients with stage IB/II/IIIA EGFR-mutated NSCLC.
Format: Microsoft PowerPoint (.ppt)
File Size: 298 KB
Released: June 1, 2020

Acknowledgements

Provided by Clinical Care Options, LLC.

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley
(203)-316-2125
skelley@clinicaloptions.com
www.clinicaloptions.com

Supported by educational grants from
AstraZeneca
Daiichi Sankyo, Inc.
Ipsen Biopharmaceuticals, Inc.
Jazz Pharmaceuticals, Inc.
Merck Sharp & Dohme Corp.

Related Content

Expert faculty reviews key clinical trials in relapsed extensive-stage small-cell lung cancer from the 2020 World Conference on Lung Cancer, from Clinical Care Options (CCO)

person default Nicolas Girard, MD, PhD Released: March 1, 2021

Podcast episode with expert insights on new data from WCLC 2020 helping to improve outcomes for patients with early-stage lung cancer, from Clinical Care Options (CCO)

Jamie E. Chaft, MD Released: February 24, 2021

Get expert insights from Clinical Care Options (CCO) on how to talk to your patients with lung or thyroid cancer about precision medicine

Marianne Davies, DNP, CNS, ACNP-BC, AOCNP Released: February 23, 2021

In this slideset from Clinical Care Options (CCO), Joel W. Neal, MD, PhD discusses antibody-drug conjugates within the clinical trial setting in NSCLC

Joel W. Neal, MD, PhD Released: February 16, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue